The official guidance on Regulating medical devices in the UK confirms this dual-system reality, and it’s one every manufacturer must now master:
➡️ https://www.gov.uk/guidance/regulating-medical-devices-in-the-uk
Under transitional rules introduced by the Medical Devices (Amendment) (Great Britain) Regulations 2023, most devices with valid CE certificates — including those under MDR and IVDR — can continue being placed on the GB market until 30 June 2030. TÜV SÜD’s regulatory summary makes this extremely clear, and it is one of the most important compliance milestones for 2025 and beyond.
The stakes are high. Misjudging which mark applies, misunderstanding MHRA timelines, or mislabelling products can lead to supply chain disruption, investigation, or loss of market access. And with the EU still accounting for around 41% of UK exports in 2024, according to the House of Commons Library, CE marking remains strategically essential for UK manufacturers targeting European markets.
What Is CE Marking?
CE marking is the EU’s conformity marking that demonstrates a device meets the regulatory requirements of EU MDR 2017/745 or IVDR 2017/746, allowing it to be freely placed on the European Economic Area (EEA) market.
For medical devices, CE certification demonstrates:
- Compliance with all General Safety and Performance Requirements (GSPRs)
- A quality management system (typically ISO 13485 aligned) overseen by an EU Notified Body for Class IIa, IIb, and III devices
- A complete technical documentation file
- A robust post-market surveillance (PMS) system
- Vigilance reporting and clinical evaluation obligations
The European Commission’s regulatory overview provides a full breakdown of these obligations.
CE marking remains strategically valuable because the EU continues to be the UK’s largest trading partner, holding 41% of UK exports in 2024. For manufacturers that sell into both EU and UK markets, keeping CE marking is not optional — it is essential.
What Is the UKCA Mark?
The UKCA mark (UK Conformity Assessed) is the post-Brexit UK product marking system for placing medical devices on the Great Britain (GB) market — England, Scotland, and Wales.
Key points:
- Governed by UK MDR 2002 (as amended)
- Relies on UK Approved Bodies, not EU Notified Bodies
- Required for manufacturers selling into GB without relying on CE transitional arrangements
Northern Ireland is a critical exception. Under the Windsor Framework, NI continues to accept CE marking, and in some cases UKNI, but not UKCA.
This means CE marking remains essential for access to:
- EU/EEA markets
- Northern Ireland
- Many international markets that reference EU MDR as their benchmark
For now, CE remains recognised in GB under device-specific transitional arrangements, but UKCA is still the long-term direction of travel.
CE Marking vs UKCA – Key Differences
Although both markings are declarations of conformity, they are governed by different laws, authorities, and market scopes.
Comparison Table
Aspect | CE Marking | UKCA Marking |
Legal Framework | EU MDR 2017/745 & IVDR 2017/746 | UK MDR 2002 as amended (including 2023 GB amendments) |
Market Coverage | EU/EEA + Northern Ireland | Great Britain only |
Conformity Assessment | EU Notified Bodies | UK Approved Bodies |
Regulator | European Commission and national Competent Authorities | MHRA (Medicines and Healthcare products Regulatory Agency) |
GB Validity | Accepted until 30 June 2030 under sector-specific transitional rules | Long-term GB compliance route once future regime begins |
See MHRA’s official medical device enforcement and compliance framework:
CE certification → CE certification requirements differ by risk class, assessment route, and notified body involvement, making early regulatory planning essential for both CE marking and future UKCA adoption.
Transition Timeline – CE and UKCA Through 2030
Medical devices have sector-specific rules separate from the general CE-recognition extension announced for non-medical products.
Key Dates Manufacturers Must Know
2024–2028 (MDD/AIMDD transitional)
CE-marked devices under MDD/AIMDD with valid certificates can be placed on the GB market until:
- 30 June 2028 (for MDD/AIMDD) or
- The expiry of their certificate, whichever is sooner.
Up to 30 June 2030 (MDR/IVDR transitional)
CE-marked devices compliant with EU MDR or IVDR may continue being placed on the GB market until 30 June 2030.
Source: TÜV SÜD summary of the 2023 transitional regulations:
Beyond 2030 (future regime)
According to MHRA’s Implementation of the Future Regulations programme, CE marking acceptance beyond 30 June 2030 is still under review as part of long-term regulatory reforms
DID YOU KNOW?
When to use CE Marking vs UKCA Mark
Use CE Marking when:
- Selling into the EU/EEA under MDR/IVDR
- Selling into Northern Ireland
- Relying on an EU Notified Body for conformity assessment
- Maintaining international approvals that reference CE certification
See the European Commission’s MDR regulatory overview:
Use the UKCA Mark when:
- Placing medical devices on the Great Britain market
- Working with a UK Approved Body under UK MDR
- Preparing for future MHRA regulatory changes
- Registering devices via MHRA’s DORS portal
Dual CE + UKCA strategy (recommended)
Most established manufacturers will need:
- CE marking → to access EU and NI
- UKCA marking → to access GB long-term
With 2030 approaching, a dual pathway ensures uninterrupted sales and reduces regulatory risk.
CE and UKCA conformity assessment routes
Both marking systems share many technical requirements based on:
- ISO 13485 quality management
- ISO 14971 risk management
- Clinical evaluation and PMS
- Technical documentation
But there are differences:
CE Marking (EU MDR/IVDR)
- Uses Notified Bodies
- Stringent clinical evidence expectations
- Full lifecycle PMS and PSUR requirements
- Harmonised EU-level guidance (MDCG)
UKCA Marking (UK MDR 2002)
- Uses Approved Bodies
- Requirements based on legacy EU directives (for now)
- Ongoing reform expected from 2025
- Distinct UK Declarations of Conformity required
Internal Link #2:
Patient Guard – ISO 13485 Consulting & Compliance Services
Labelling and documentation requirements
CE Marking label requirements:
- CE symbol
- Manufacturer name and address
- EU Authorised Representative (for non-EU manufacturers)
- Notified Body number (if applicable)
UKCA label requirements:
- UKCA symbol
- Manufacturer’s UK address or UK Responsible Person (UKRP)
- UK Approved Body number (if applicable)
Manufacturers selling into both regions typically maintain:
- A shared Technical File
- A shared QMS
- Separate EU and UK Declarations of Conformity referencing the correct laws:
- EU MDR 2017/745 or IVDR 2017/746
- UK MDR 2002 as amended
Common compliance mistakes to avoid
Manufacturers navigating CE and UKCA simultaneously often run into preventable issues:
Relying on expired or directive-based CE certificates
MDD/AIMDD certificates must meet transitional rules to remain valid.
Forgetting the UK Responsible Person (UKRP)
Non-UK manufacturers must appoint a UKRP for UKCA/GB placement.
Poor labelling strategy
Mixing CE and UKCA incorrectly on the same label is a common audit finding.
Documentation inconsistencies
EU MDR risk files, PMS data, and clinical evaluation must match UK files; misalignment triggers MHRA corrective action.
5-Minute CE/UKCA Audit Checklist
- Do we have valid CE certificates (MDR/IVDR or MDD/AIMDD transitional)?
- Is our UKRP appointed and listed correctly?
- Are our labels correct for each market?
- Do we maintain separate EU and UK Declarations of Conformity?
- Are we preparing now for the 2030 UKCA deadline?
Future outlook – MHRA reforms and global alignment
MHRA’s future regime aims to bring the UK closer to IMDRF principles, with increased focus on:
- Stronger PMS
- Enhanced risk management
- Clear software/AI pathways
- Uprated clinical evidence requirements
The government has already announced an indefinite CE extension for many non-medical sectors, hinting at a long-term pragmatic alignment trend. For medical devices, transitional timelines remain structured through 2030.
Patient Guard helps manufacturers build regulatory strategies that work across CE, UKCA, FDA, and emerging global markets. Get in touch to find out how we can support you.
Conclusion
CE marking remains the dominant compliance route for European and Northern Irish markets — and, under current transitional rules, for Great Britain until 30 June 2030. UKCA marking represents the long-term direction of UK medical device regulation, but manufacturers have time to transition if they plan strategically.
Given Europe’s 41% share of UK exports, the smartest approach for most manufacturers is clear: maintain CE certification while gradually implementing UKCA in line with MHRA’s evolving guidance.
Need help with CE or UKCA compliance? Patient Guard supports full technical documentation, ISO 13485 alignment, UKRP appointment, and MHRA device registration. Speak to one of our experts today.
FAQ – ISO 10993-1:2025 and Biological Evaluation
CE marking applies to EU/EEA markets and NI; UKCA applies to Great Britain. They use different regulations and conformity bodies.
Yes — CE marking is valid on the GB market for medical devices until 30 June 2030 under the 2023 transitional rules.
Current guidance indicates 2030 as the earliest full-transition date for medical devices, though MHRA reforms may adjust long-term requirements.
If you sell into both EU and GB markets, yes — dual compliance is essential.
Through the DORS system, with CE marking accepted under current transitional rules
Yes, from ISO 13485 QMS support to UKRP representation and label reviews.
Patient Guards Recent Posts
Medical Device Technical File: Structure & Requirements
A poorly structured medical device technical file is one of the fastest ways to trigger audit findings, Notified Body delays, or regulatory pushback, even when all the “right” documents technically exist.
IVD Consultancy: Practical IVDR Compliance Strategies
IVDR has fundamentally reshaped the regulatory landscape for in vitro diagnostic devices, and, yes, it’s still catching many manufacturers off guard years after its implementation.
Top 5 Quality Management System Failures to Prevent
Even the most sophisticated medical device companies can stumble when their quality management system (QMS) fails. When that happens, it’s rarely a minor inconvenience – it is more often a chain reaction of recalls, warning letters, certificate suspensions, and huge remediation bills.
